FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387609670> ?p ?o ?g. }

• W4387609670 abstract "<div>AbstractPurpose:<p>Alhough antiangiogenic agents are the bedrock of treatment for radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), novel antiangiogenic agents with optimized features like greater target-binding affinities and more favorable pharmacokinetics profile are needed. This phase II randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of anlotinib, a multikinase inhibitor, for RAIR-DTC.</p>Patients and Methods:<p>Patients (ages between 18 and 70 years) with pathologically confirmed locally advanced or metastatic RAIR-DTC were enrolled and randomly received 12 mg anlotinib once daily or placebo on day 1 to 14 every 3 weeks. Patients on placebo were allowed to receive open-label anlotinib after disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS) and safety.</p>Results:<p>Between September 2015 and August 2018, 76 and 37 patients randomly received anlotinib and placebo, respectively. Patients receiving anlotinib had a significantly longer median PFS [40.5 months, 95% confidence interval (CI), 28.3–not estimable (NE) versus placebo 8.4 months, 95% CI, 5.6–13.8; HR = 0.21, 95% CI, 0.12–0.37, <i>P</i> < 0.001], meeting the primary endpoint. OS was still immature, with a trend of benefit with anlotinib (HR = 0.57, 95% CI, 0.29–1.12). All patients in the anlotinib group experienced adverse events (AE); 8 (10.5%) discontinued treatment due to AEs.</p>Conclusions:<p>Anlotinib demonstrated promising efficacy and favorable tolerance in the treatment of locally advanced or metastatic RAIR-DTC, supporting further research to establish its role in the treatment of this serious disease.</p></div>" @default.
• W4387609670 created "2023-10-14" @default.
• W4387609670 creator A5003118713 @default.
• W4387609670 creator A5007073787 @default.
• W4387609670 creator A5012390410 @default.
• W4387609670 creator A5015186555 @default.
• W4387609670 creator A5027051284 @default.
• W4387609670 creator A5036822473 @default.
• W4387609670 creator A5036948980 @default.
• W4387609670 creator A5038677051 @default.
• W4387609670 creator A5048095374 @default.
• W4387609670 creator A5052607264 @default.
• W4387609670 creator A5055636739 @default.
• W4387609670 creator A5055922518 @default.
• W4387609670 creator A5057704753 @default.
• W4387609670 creator A5060184563 @default.
• W4387609670 creator A5076582862 @default.
• W4387609670 creator A5082728678 @default.
• W4387609670 creator A5083549596 @default.
• W4387609670 creator A5085748409 @default.
• W4387609670 creator A5088323967 @default.
• W4387609670 date "2023-10-13" @default.
• W4387609670 modified "2023-10-14" @default.
• W4387609670 title "Data from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial" @default.
• W4387609670 doi "https://doi.org/10.1158/1078-0432.c.6879423.v1" @default.
• W4387609670 hasPublicationYear "2023" @default.
• W4387609670 type Work @default.
• W4387609670 citedByCount "0" @default.
• W4387609670 crossrefType "posted-content" @default.
• W4387609670 hasAuthorship W4387609670A5003118713 @default.
• W4387609670 hasAuthorship W4387609670A5007073787 @default.
• W4387609670 hasAuthorship W4387609670A5012390410 @default.
• W4387609670 hasAuthorship W4387609670A5015186555 @default.
• W4387609670 hasAuthorship W4387609670A5027051284 @default.
• W4387609670 hasAuthorship W4387609670A5036822473 @default.
• W4387609670 hasAuthorship W4387609670A5036948980 @default.
• W4387609670 hasAuthorship W4387609670A5038677051 @default.
• W4387609670 hasAuthorship W4387609670A5048095374 @default.
• W4387609670 hasAuthorship W4387609670A5052607264 @default.
• W4387609670 hasAuthorship W4387609670A5055636739 @default.
• W4387609670 hasAuthorship W4387609670A5055922518 @default.
• W4387609670 hasAuthorship W4387609670A5057704753 @default.
• W4387609670 hasAuthorship W4387609670A5060184563 @default.
• W4387609670 hasAuthorship W4387609670A5076582862 @default.
• W4387609670 hasAuthorship W4387609670A5082728678 @default.
• W4387609670 hasAuthorship W4387609670A5083549596 @default.
• W4387609670 hasAuthorship W4387609670A5085748409 @default.
• W4387609670 hasAuthorship W4387609670A5088323967 @default.
• W4387609670 hasConcept C121332964 @default.
• W4387609670 hasConcept C126322002 @default.
• W4387609670 hasConcept C126894567 @default.
• W4387609670 hasConcept C142424586 @default.
• W4387609670 hasConcept C142724271 @default.
• W4387609670 hasConcept C143998085 @default.
• W4387609670 hasConcept C168563851 @default.
• W4387609670 hasConcept C197934379 @default.
• W4387609670 hasConcept C203092338 @default.
• W4387609670 hasConcept C204787440 @default.
• W4387609670 hasConcept C27081682 @default.
• W4387609670 hasConcept C2776694085 @default.
• W4387609670 hasConcept C2780739268 @default.
• W4387609670 hasConcept C2993294228 @default.
• W4387609670 hasConcept C31760486 @default.
• W4387609670 hasConcept C44249647 @default.
• W4387609670 hasConcept C526584372 @default.
• W4387609670 hasConcept C535046627 @default.
• W4387609670 hasConcept C71924100 @default.
• W4387609670 hasConcept C87355193 @default.
• W4387609670 hasConcept C90924648 @default.
• W4387609670 hasConceptScore W4387609670C121332964 @default.
• W4387609670 hasConceptScore W4387609670C126322002 @default.
• W4387609670 hasConceptScore W4387609670C126894567 @default.
• W4387609670 hasConceptScore W4387609670C142424586 @default.
• W4387609670 hasConceptScore W4387609670C142724271 @default.
• W4387609670 hasConceptScore W4387609670C143998085 @default.
• W4387609670 hasConceptScore W4387609670C168563851 @default.
• W4387609670 hasConceptScore W4387609670C197934379 @default.
• W4387609670 hasConceptScore W4387609670C203092338 @default.
• W4387609670 hasConceptScore W4387609670C204787440 @default.
• W4387609670 hasConceptScore W4387609670C27081682 @default.
• W4387609670 hasConceptScore W4387609670C2776694085 @default.
• W4387609670 hasConceptScore W4387609670C2780739268 @default.
• W4387609670 hasConceptScore W4387609670C2993294228 @default.
• W4387609670 hasConceptScore W4387609670C31760486 @default.
• W4387609670 hasConceptScore W4387609670C44249647 @default.
• W4387609670 hasConceptScore W4387609670C526584372 @default.
• W4387609670 hasConceptScore W4387609670C535046627 @default.
• W4387609670 hasConceptScore W4387609670C71924100 @default.
• W4387609670 hasConceptScore W4387609670C87355193 @default.
• W4387609670 hasConceptScore W4387609670C90924648 @default.
• W4387609670 hasLocation W43876096701 @default.
• W4387609670 hasOpenAccess W4387609670 @default.
• W4387609670 hasPrimaryLocation W43876096701 @default.
• W4387609670 hasRelatedWork W1666348496 @default.
• W4387609670 hasRelatedWork W1987273470 @default.
• W4387609670 hasRelatedWork W2009096079 @default.
• W4387609670 hasRelatedWork W2142415310 @default.
• W4387609670 hasRelatedWork W2546048320 @default.
• W4387609670 hasRelatedWork W2887409860 @default.
• W4387609670 hasRelatedWork W2910926762 @default.

• next